MYRIAD GENETICS INC (MYGN)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for MYGN
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| MYGN | Former Executive Chairman, Amneal Pharmaceuticals, Inc. and President and Chief Executive Officer, Impax Laboratories, Inc.; Director | 65 | ["More than 30 years of generic and branded pharmaceutical experience","Executive Chairman of Amneal Pharmaceuticals, Inc.","President and CEO of Impax Laboratories, Inc.","Executive Chairman of Allergan, plc","President and CEO of Actavis, plc","President, Chief Operating Officer of Barr Pharmaceuticals, Inc.","General Counsel of Barr","Senior Consultant with Arthur Andersen & Co.","Undergraduate degree in General Studies from the University of Michigan","J.D. from Catholic University of America","BoardDiversity","Finance and Accounting","Leadership","HealthcareIndustry","Technology"] | ["CHCC","RPIC"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| ZTS | Former Executive Chairman of Amneal Pharmaceuticals, Inc.; Independent Director | 65 | ["Exceptional global healthcare and pharmaceutical industry expertise","Former Executive Chairman of Amneal Pharmaceuticals, Inc.","Prior senior executive leadership roles including President and CEO of Actavis","Executive Chairman of Allergan","Deep knowledge of manufacturing processes, R&D, product liability and regulatory matters","Valuable strategic M&A acumen","Legal background as a former public company general counsel","Extensive public company board experience","Strong legal and governance expertise"] | ["Corporate Governance","Quality and Innovation","Corporate Governance Committee","Quality and Innovation Committee"] | 2026 |
| ZBH | [] | ["Audit Committee", "Compensation and Management Development Committee"] | 2017 |
Biography sourced from the proxy statement filing.
Paul M. Bisaro has served as a director of Myriad since October 31, 2022. Mr. Bisaro is an accomplished global business leader with more than 30 years of generic and branded pharmaceutical experience. He currently serves as a director of Keenova Therapeutics plc (formally Mallinckrodt plc) and has served as the Chair of the Governance and Compliance Committee. Mr. Bisaro previously served as Chairman of the board of directors of Mallinckrodt from February 2024 through its transition and rebrand as Keenova Therapeutics in November 2025, and also served as its Chairman of the Board during a prior term from June 2022 to November 2023. Mr. Bisaro is also currently a member of the board of directors of Zoetis Inc. He previously served on the board of Zimmer Biomet Holding, Inc. and TherapueticsMD. Mr. Bisaro s executive experience includes serving as the Executive Chairman of Amneal Pharmaceuticals, Inc., from May 2018 until August of 2019. Prior to that role, from May 2017 to May 2018, he was President and Chief Executive Officer, and member of the board of directors, of Impax Laboratories, Inc., until its acquisition by Amneal Pharmaceuticals. Mr. Bisaro also served as Executive Chairman of Allergan, plc, from July 2014 to November 2016, and as President and CEO of Actavis, plc (and its predecessor firm Watson Pharmaceuticals Inc.) from September 2007 to July 2014. Mr. Bisaro served on the board of directors of Allergan (and its predecessor firms) from September 2007 until August 2018. Earlier in his career, he served as President, Chief Operating Officer, and a member of the board of directors of Barr Pharmaceuticals, Inc., from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds and served as a Senior Consultant with Arthur Andersen & Co. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a J.D. from Catholic University of America in Washington, D.C. The Board has determined that Mr. Bisaro should serve on the Board based on his more than 25 years of business, management and leadership experience in the pharmaceutical industry and his proven track record of driving company growth through operational execution and corporate transformation. His extensive experience as a public company director, including his leadership as a board chair through complex corporate transformations, provides our Board with deep expertise in mergers and acquisitions, finance, accounting, and legal matters. Age: 65 Director Since: 2022 Committees: